Main Menu Pioneering the discovery and development of cortisol modulators Developing cortisol modulators for a broad range of serious diseases, including endocrine, metabolic, oncologic, and psychiatric disorders Commitment to Science We lead the field in the research and development of selective glucocorticoid receptor (GR) antagonists. Impact of excess cortisol and understanding GR antagonism LEARN MORE Research & Pipeline LEARN MORE Commitment to Patients We are committed to developing novel medications for patients suffering from diseases driven by cortisol dysregulation. LEARN MORE Commitment to Culture We foster a diverse and collaborative environment focused on developing novel therapies that help treat people with serious unmet medical needs. LEARN MORE About Executive Team Board of Directors Educational Grants Contact Us Product Korlym for Cushing Syndrome Medical Information Request Patients Research & Pipeline Cortisol Modulation Cortisol Modulation Therapeutic Platform Pipeline and Clinical Trials Publications Investigator-Initiated Studies Compassionate Use Investors Investors Overview Press Releases Events Corporate Governance Analyst Coverage Stock Information SEC Filings Careers Benefits Testimonials Current Opportunities © 2021 Corcept Privacy Policy Terms of Use Site Map We use cookies to evaluate and improve your user experience on our website, to analyze our website traffic, and for advertising purposes. To learn more about how we use cookies, and how to change your cookie settings, please visit our Privacy Policy. By continuing to use our site you consent to our use of cookies. ACKNOWLEDGED